168O Pooled Analysis of the Prognostic and Predictive Value of Kras Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer (Nsclc) Treated with Egfr Tkis (E-Tki)

Aim: Subset analyses from 9 randomized trials report conflicting results concerning the ability of KRAS mutation (M+) status to predict benefit from E-TKIs. This pooled analysis of 4 trials of E-TKIs v placebo was conducted to clarify the prognostic/predictive roles of KRAS M+ and to explore the importance of M+ subtype. Methods: Data were pooled for patients with known KRAS status from 4 trials of E-TKI v placebo (NCIC CTG BR.21 & TOPICAL - …